IGF-1 LR3 — Benefits & User Experiences
Long-chain analogue of insulin-like growth factor 1 with extended half-life. Binds IGF-1 receptors to promote muscle protein synthesis and cellular growth.
1 anonymous report
Also known as:
igf1lr3igf-1lr3igf lr3long r3 igfigf1
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Community Q&A
- What does IGF-1 LR3 do?
- Community accounts describe IGF-1 LR3 primarily as a muscle protein synthesis amplifier — acting on IGF-1 receptors throughout the body rather than locally like MGF. The most consistently described effect: accelerated muscle recovery and growth when combined with resistance training, with body composition changes visible within 4–6 weeks. Hypoglycaemia appears as the most commonly cited risk — accounts consistently mention monitoring blood glucose and avoiding dosing on an empty stomach.
- How long does IGF-1 LR3 stay active?
- Community accounts describe the half-life as approximately 20–30 hours, consistent with once-daily dosing being the dominant protocol in confessions. The Long R3 modification prevents binding to IGF binding proteins, which extends activity but means systemic rather than localised action. Accounts describe dosing post-workout in the majority of reports. Cycle lengths in community accounts range from 4 to 6 weeks, with planned breaks to prevent receptor downregulation.
- What are the risks of IGF-1 LR3?
- Community accounts describe two primary risk categories. Hypoglycaemia is the most immediately dangerous — accounts consistently describe monitoring blood glucose, dosing post-meal rather than fasted, and keeping fast-acting carbohydrates available. Some accounts describe hypoglycaemic episodes at standard doses. The second risk: growth promotion is non-selective — IGF-1 stimulates all IGF-receptor-expressing tissue, not just muscle. Accounts express concern about this for existing conditions where tissue growth is a risk. Acral and jaw growth reports appear in accounts from users running IGF-1 LR3 continuously for many months. The community framing: hypoglycaemia is the real, immediate, manageable risk; long-term growth concerns inform the short-cycle convention.
- How do community accounts dose IGF-1 LR3?
- Accounts cluster around 20–100mcg per day subcutaneous or intramuscular, post-workout. The range is wide and source-dependent — accounts consistently recommend starting at the low end (20–30mcg) on any new supply. Post-workout timing appears in the majority of accounts, with elevated nutrient partitioning cited as amplifying the effect. Cycle length of 4–6 weeks with planned breaks is the near-universal recommendation, attributed to receptor downregulation with continuous exposure.